ConductScience.org, home

Library / Trial comparisons

Saxagliptin vs Placebo: Participants With Any Event From the Composite of Cardiovascular Death (CV Death), Non-fatal Myocardial Infarction (MI), or Non-fatal Ischaemic Stroke

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.0740.06860.0799wilsonClinicalTrials.gov
Risk in group 20.07420.06870.08wilsonClinicalTrials.gov
Risk difference, group 1 minus group 2-0.000126-0.008130.00788newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 20.9980.8961.11logClinicalTrials.gov
Odds ratio, group 1 over group 20.9980.8881.12logClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on Saxagliptin than on Placebo7,940from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Saxagliptin5 mg once daily in subjects with normal renal function or mild impaired renal function (eGFR \>50 mL/min); 2.5 mg once daily in subjects with moderate to severe renal impairment (eGFR ≤50 mL/min).6138,280OG000ClinicalTrials.gov
Group 2PlaceboMatching Placebo6098,212OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypePRIMARYClinicalTrials.gov
TitleParticipants With Any Event From the Composite of Cardiovascular Death (CV Death), Non-fatal Myocardial Infarction (MI), or Non-fatal Ischaemic StrokeClinicalTrials.gov
Description
Participants with CV death, non-fatal MI or non-fatal ischaemic stroke. If no event, censoring occurs at the patient withdrawal of consent, last contact, or death (when applicable)-whichever was later.
ClinicalTrials.gov
Time frameRandomization (day 0) up to 2.9 yearsClinicalTrials.gov
PopulationIntention To Treat (ITT) analysis of randomized population. Events were adjudicated by the Clinical Event Adjudication Committee.ClinicalTrials.gov

Trial 8

FieldValueSource
TitleDoes Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes MedicationsClinicalTrials.gov
NCT numberNCT01107886ClinicalTrials.gov
PhasesPHASE4ClinicalTrials.gov
ConditionsType 2 Diabetes MellitusClinicalTrials.gov
InterventionsSaxagliptin, PlaceboClinicalTrials.gov
Lead sponsorAstraZenecaClinicalTrials.gov
Results first posted2014-06-13ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT01107886?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.